Combining basal insulin with a GLP-1 inhibitor not only may produce favorable reductions in A1c values, but may also lower the risk for hypoglycemia and promote weight loss, reports Dr John Buse.

Many people eat this menu item every day without realizing how much sodium it contributes to their diet, reports Dr Jeffrey Berns.

The FDA is looking more closely into the safety of approved testosterone products. In the meantime, what do we know about treating low T?

Dr Gerald Chodak discusses an FDA panel's recommendation to change labels on testosterone-replacement products in order to discourage their use in 'low T' cases.

EASD President Andrew Boulton reflects on how lessons learned from WWI could help address the current epidemic of diabetes.

Dr Anne Peters talks with Dr Mattias Blüher about the latest research on brown adipose tissue and the clinical applications under study.

Urogenital dysfunction, walking impairment, and pain are common complications of diabetic neuropathy. Solomon Tesfaye comments on the latest EASD studies in this field.

Gastro-enteropancreatic hormones and their clinical counterparts, medications based on GLP-1, are an active field of research. Michael Nauck, MD, summarizes the latest EASD studies on this topic.

Dr Anne Peters talks with Dr Aus Alzaid about the high rate of diabetes in Saudi Arabia, and the unique cultural considerations in managing and preventing diabetes in the Middle East.

Can community-based programs lower the type 2 diabetes rate by engaging those most at risk?